This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| TSC1 | |
|---|---|
| Name | TSC1 |
| Other names | hamartin |
| Organism | Homo sapiens |
| Gene id | 7248 |
| Location | Chromosome 9 |
TSC1 TSC1 encodes hamartin, a protein central to a conserved signalling hub that regulates cell growth and proliferation. The gene and protein interact with multiple conserved pathways first characterized in studies of mTOR signalling, with implications across fields from clinical genetics to oncology and neuroscience. Mutations in the locus cause a multisystem disorder studied by researchers at institutions including NIH, Massachusetts General Hospital, and Great Ormond Street Hospital.
TSC1 was identified through positional cloning efforts that involved researchers from St. Jude Children's Research Hospital, University of Cambridge, and the Howard Hughes Medical Institute; the discovery paralleled work on TSC2 by teams at Harvard Medical School and University of California, San Francisco. Hamartin forms a complex with tuberin that was biochemically linked to the mechanistic target of rapamycin pathway elucidated in laboratories such as Whitehead Institute and Max Planck Institute. Studies in model organisms including Drosophila melanogaster, Caenorhabditis elegans, and Mus musculus demonstrated conserved roles, informing translational research at centres like Broad Institute and Dana-Farber Cancer Institute.
The TSC1 locus maps to Chromosome 9 (human chromosome 9) and comprises multiple exons revealed in genomic projects led by Human Genome Project investigators. Hamartin is a peripheral membrane-associated protein with coiled-coil domains characterized by structural biologists at Cold Spring Harbor Laboratory and Scripps Research. Protein interaction maps from groups at European Molecular Biology Laboratory and Stanford University show binding interfaces between hamartin and tuberin, with post-translational modifications mapped by proteomics consortia at EMBL-EBI and ProteomeXchange. Comparative genomics in datasets from Ensembl and UCSC Genome Browser shows conserved motifs across vertebrates and invertebrates traced by researchers at Wellcome Sanger Institute.
Hamartin operates as a scaffold within a heterodimeric complex that negatively regulates Rheb and downstream mTOR Complex 1 signalling, a mechanism detailed in landmark studies from Yale University and University of Toronto. The complex integrates inputs from growth factor receptors studied at Rockefeller University, energy sensors such as AMP-activated protein kinase characterized at University of Cambridge, and stress pathways investigated by teams at Cold Spring Harbor Laboratory. Cellular consequences include control of protein synthesis, autophagy, and cytoskeletal dynamics probed in labs at Johns Hopkins University and ETH Zurich. Cross-talk with pathways modulated by proteins studied at National Cancer Institute and European Institute of Oncology places hamartin at a nexus relevant to cell size regulation in tissues examined by pathology groups at Mayo Clinic.
Germline loss-of-function variants produce a multisystem condition historically managed at centres such as Boston Children's Hospital and Great Ormond Street Hospital. Clinical manifestations involve benign tumours, cortical malformations studied in cohorts at University College London, and renal angiomyolipomas monitored at Cleveland Clinic. Neurological features including epilepsy and neurodevelopmental delay have been characterized in longitudinal studies coordinated by European Reference Network and National Institutes of Health. TSC1-related disease has implications for oncologic risk assessed by registries at International Association for the Study of Lung Cancer and nephrology consortia at American Society of Nephrology.
Diagnostic criteria were refined through consensus conferences involving experts from American Academy of Pediatrics and European Society of Human Genetics. Molecular testing uses targeted sequencing panels developed by clinical laboratories at Mayo Clinic Laboratories and Quest Diagnostics, whole-exome approaches from Broad Institute, and copy-number assays standardized by College of American Pathologists. Variant interpretation follows guidelines promulgated by American College of Medical Genetics and Genomics and international variant databases curated by groups at ClinGen and DECIPHER. Prenatal, carrier, and cascade testing practices are implemented in programmes at Johns Hopkins Hospital and community genetics services affiliated with Kaiser Permanente.
mTOR inhibitors such as rapamycin and everolimus, with pivotal trials conducted by consortia including European Organisation for Research and Treatment of Cancer and Cooperative Trials Group, reduce lesion size and seizure burden in many patients. Multidisciplinary care models at Children's Hospital of Philadelphia and UCSF Benioff Children's Hospital integrate neurology, nephrology, dermatology, and pulmonology expertise. Surgical strategies originate from teams at Mayo Clinic and Mount Sinai Hospital for refractory lesions and epilepsy surgery protocols developed at Cleveland Clinic. Emerging approaches involve precision medicine initiatives at NIH Clinical Center and gene therapy platforms under investigation at University of Pennsylvania and biotech companies collaborating with Bill & Melinda Gates Foundation-funded consortia.
Animal and cellular models remain central: knockout and conditional alleles in Mus musculus created at Jackson Laboratory reproduce organ-specific phenotypes; mosaic models in Drosophila and organoids developed at Hubrecht Institute and Hub and Spoke labs enable mechanistic dissection. High-throughput screens at Broad Institute and CRISPR platforms from Addgene identify modifiers and drug candidates. International collaborative networks such as Tuberous Sclerosis Complex Alliance and registries coordinated by European Reference Network drive natural history studies and clinical trials. Future directions connect basic research hubs like Max Planck Institute for Molecular Cell Biology and Genetics with translational centres at Stanford University School of Medicine to advance genotype–phenotype mapping and therapeutic innovation.
Category:Genes